Table 2b.
New users, switchers and stoppers of COC before and after EMA recommendations (Denmark)
| COC users | Total PY |
IR per 1000 PY (95% CI) |
COC users | Total PY |
IR per 1000 PY (95% CI) |
|
|---|---|---|---|---|---|---|
| Time Period 1⁎ | Time Period 2⁎ | |||||
| New users | 66,526 | 1,800,531 | 37.0 (36.7–37.2) | 59,880 | 1,839,266 | 32.6 (32.3–32.8) |
| Levonorgestrel | 40,803 (61.3%) | 1,800,531 | 22.7 (22.4–22.9) | 44,662(74.6%) | 1,839,266 | 24.3 (24.1–24.5) |
| Norethisterone | 44 (0.1%) | 1,800,531 | 0.0 (0.0–0.0) | 0 (0%) | 1,839,266 | 0.0 (0.0–0.0) |
| Norgestimate | 8010 (12.0%) | 1,800,531 | 4.5 (4.4–4.6) | 5087 (8.5%) | 1,839,266 | 2.8 (2.7–2.8) |
| Gestodene | 6604 (9.9%) | 1,800,531 | 3.7 (3.6–3.8) | 3369 (5.6%) | 1,839,266 | 1.8 (1.8–1.9) |
| Desogestrel | 4850 (7.3%) | 1,800,531 | 2.7 (2.6–2.8) | 2454 (4.1%) | 1,839,266 | 1.3 (1.3–1.4) |
| Drospirenone | 2330 (3.5%) | 1,800,531 | 1.3 (1.2–1.4) | 1534 (2.6%) | 1,839,266 | 0.8 (0.8–0.9) |
| Nomegestrol | 107 (0.2%) | 1,800,531 | 0.1 (0.1–0.1) | 315 (0.5%) | 1,839,266 | 0.2 (0.2–0.2) |
| Dienogest | 1532 (2.3%) | 1,800,531 | 0.9 (0.8–0.9) | 725 (1.2%) | 1,839,266 | 0.4 (0.4–0.4) |
| Cyproterone acetate | 2246 (3.4%) | 1,800,531 | 1.3 (1.2–1.3) | 1734 (2.9%) | 1,839,266 | 0.9 (0.9–1.0) |
| Switchers (different type)⁎⁎ | 118,670 | 445,980 | 266.1 (264.6–267.6) | 57,265 | 476,207 | 120.3 (119.3–121.2) |
| Safest to Other | 7539 (6.4%) | 114,048.9 | 66.1 (64.6–67.6) | 11,246 (19.6%) | 293,416.5 | 38.3 (37.6–39.0) |
| Other to Safest | 81,605 (68.8%) | 331,931.1 | 245.9 (244.2–247.5) | 33,119 (57.8%) | 182,790.3 | 181.2 (179.2–183.1) |
| Stoppers | 169,168 | 445,980 | 379.3 (377.5–381.1) | 162,928 | 476,207 | 342.1 (340.5–343.8) |
| Safest | 45,760 (27.1%) | 114,048.9 | 401.2 (397.6–404.9) | 98,648 (60.6%) | 293,416.5 | 336.2 (334.1–338.3) |
| Other | 123,408 (73.0%) | 331,931.1 | 371.8 (369.7–373.9) | 64,280 (39.5%) | 182,790.3 | 351.7 (348.9–354.4) |
Safest group consists of progestogens levonorgestrel, norethisterone, norgestimate.
Other group consists of progestogens desogestrel, gestodene, drospirenone, cyproterone, nomegestrol, dienogest.
COC, combined oral contraceptives; EMA, European Medicines Agency; PY, person-years; IR, incidence rate; CI, confidence interval.
⁎
Time period 1 (1 January 2012 to 31 January 2014) and Time period 2 (1 February 2014 to 29 February 2016) refers to the periods before and after the European Medicines Agency (EMA) review and recommendation, respectively.
⁎⁎
Switching between different types means between progestogens (not between different doses).